inhaled interferon beta-1a

Inhaled interferon beta-1a is an investigational formulation of the recombinant human cytokine interferon beta-1a, developed by Trio Medicines Ltd. for the treatment of multiple sclerosis. Unlike standard formulations such as Avonex (intramuscular) or Rebif (subcutaneous), this version is delivered via inhalation to potentially improve patient convenience or alter the pharmacokinetic profile. Interferon beta-1a acts as an immunomodulator by binding to type I interferon receptors (IFNAR1 and IFNAR2), leading to the activation of JAK-STAT signaling pathways and the expression of antiviral and anti-inflammatory genes. In clinical trials, it has been evaluated for its safety, tolerability, and pharmacodynamic effects (e.g., serum neopterin levels) compared to traditional delivery methods.

Other names

inhaled formulation of interferon beta-1ainhaled Avonex